GO:0002841 negative regulation of T cell mediated immune response to tumor cell: Immune Evasion Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0002841 describes any process that stops, prevents, or reduces the frequency, rate, or extent of a T cell mediated immune response to tumor cells.
• This biological process is a central mechanism of tumor immune evasion and a major barrier to cancer immunotherapy.
• Key regulators include immune checkpoint molecules such as CTLA-4 and PD-L1, which suppress CD8+ T cell effector functions.
• The tumor microenvironment, including cancer-associated fibroblasts, bile acids, and microbiota-modulated T cells, actively drives negative regulation of anti-tumor T cell responses.
• Tumor-associated NK cells and CD8+ T cell differentiation programs contribute to resistance against immune checkpoint blockers.
• Experimental dissection of GO:0002841 relies on CRISPR knockout, knock-in, overexpression models, and functional immune assays.
Description
GO:0002841, negative regulation of T cell mediated immune response to tumor cell, is a biological process that encompasses any mechanism which stops, prevents, or reduces the frequency, rate, or extent of T cell mediated killing of tumor cells. This process is fundamental to cancer immunology because tumors that successfully evade T cell attack can grow and metastasize despite an intact immune system. Understanding the molecular players that enforce this negative regulation is essential for developing therapies that restore anti-tumor immunity. The term is defined in QuickGO as any process that stops, prevents, or reduces the frequency, rate, or extent of a T cell mediated immune response to tumor cell. It includes both cell-intrinsic checkpoints in T cells and extrinsic suppressive signals from the tumor microenvironment. Research into GO:0002841 has been propelled by the clinical success of immune checkpoint blockade, which functionally reverses this negative regulation and unleashes CD8+ T cell cytotoxicity. Key studies have shown that CTLA-4 blockade enhances antitumor immunity by removing a brake on T cell activation, while PD-1 blockade inhibits adaptive immune resistance in tumors. More recent work has revealed that CD8+ T cells can regulate tumor ferroptosis during immunotherapy, and that tumor-associated NK cells shape distinct CD8+ T cell differentiation programs that contribute to resistance against immune checkpoint blockers. These findings underscore that negative regulation of T cell mediated immune response to tumor cell is not a single pathway but a network of cellular and molecular interactions.
negative regulation of T cell mediated immune response to tumor cell At A Glance
| GO ID | GO:0002841 |
|---|---|
| GO term | negative regulation of T cell mediated immune response to tumor cell |
| Ontology | biological_process |
| Synonym | inhibition of T cell mediated immune response to tumor cell; downregulation of T cell mediated immune response to tumor cell; negative regulation of T-lymphocyte mediated immune response to tumor cell |
| Major function | Suppression or dampening of T cell mediated killing of tumor cells, contributing to tumor immune evasion |
| Related processes | Immune checkpoint signaling, T cell exhaustion, tumor microenvironment immunosuppression |
| Key cell types | CD8+ T cells, regulatory T cells, tumor-associated macrophages, cancer-associated fibroblasts |
| Disease relevance | Cancer immunotherapy resistance, tumor progression, autoimmune disease (when dysregulated) |
What Is GO:0002841?
In your own words, GO:0002841 refers to any biological process that reduces, blocks, or prevents the ability of T cells to mount an effective immune response against tumor cells. This includes mechanisms that dampen T cell activation, proliferation, effector function, or survival in the context of a tumor. The QuickGO definition states: Any process that stops, prevents, or reduces the frequency, rate, or extent of a T cell mediated immune response to tumor cell. It is a negative regulatory biological process that is critical for understanding tumor immune evasion and resistance to immunotherapy.
Why Is negative regulation of T cell mediated immune response to tumor cell Important in Cell Biology?
GO:0002841 is critically important because it represents the primary obstacle to successful cancer immunotherapy. Tumors exploit multiple mechanisms to negatively regulate T cell mediated immune responses, including checkpoint molecule expression, secretion of immunosuppressive metabolites, and recruitment of suppressive cell types. Understanding this process at a molecular level allows researchers to identify therapeutic targets that can be blocked to restore anti-tumor immunity. Moreover, resistance to immune checkpoint blockers often arises from additional layers of negative regulation, such as those mediated by tumor-associated NK cells or microbiota-derived signals. Therefore, studying GO:0002841 is essential for developing next-generation immunotherapies and predictive biomarkers.
• It is the central mechanism by which tumors evade T cell mediated killing, directly impacting cancer progression and patient survival.
• It is the functional target of immune checkpoint inhibitors such as anti-CTLA-4 and anti-PD-1/PD-L1 antibodies.
• It contributes to resistance against immune checkpoint blockers, a major clinical challenge.
• It involves metabolic and microbiota-derived signals, such as bile acids, that suppress CD8+ T cell effector functions.
• It is modulated by the tumor microenvironment, including cancer-associated fibroblasts that drive T cell dysfunction.
• It intersects with T cell differentiation programs and ferroptosis regulation during immunotherapy.
• It is regulated by epigenetic and post-transcriptional mechanisms, such as m6A-modified circIGF2BP3 promoting PD-L1 deubiquitination.
• It provides a conceptual framework for identifying new therapeutic targets to enhance anti-tumor immunity.
• It is relevant to autoimmune diseases where excessive negative regulation may contribute to immune escape of malignant cells.
• It is a key area for CRISPR-based functional genomics to discover novel regulators.
What Happens During negative regulation of T cell mediated immune response to tumor cell?
Initiation by Tumor-Derived Signals
In simple terms: Tumors send out signals that tell T cells to slow down or stop attacking.
The process begins when tumor cells or their microenvironment produce factors that engage inhibitory receptors on T cells. For example, tumor cells can express PD-L1, which binds to PD-1 on T cells and delivers inhibitory signals. Similarly, CTLA-4 on T cells competes with CD28 for co-stimulatory ligands, thereby reducing T cell activation. These initial signals set the stage for negative regulation of T cell mediated immune response to tumor cell.
Amplification by Immunosuppressive Microenvironment
In simple terms: Other cells around the tumor help to reinforce the suppression of T cells.
Cancer-associated fibroblasts (CAFs) can drive T cell dysfunction through secreted factors such as AEBP1, creating a barrier to effective anti-tumor immunity. Additionally, microbiota-modified bile acids can suppress CD8+ T cell effector functions, promoting colorectal cancer growth. Regulatory T cells and immunosuppressive intestinal T cells can also be recruited into tumors to dampen T cell responses. These microenvironmental components amplify the negative regulation initiated by tumor cells.
T Cell Intrinsic Dysfunction and Exhaustion
In simple terms: T cells themselves become exhausted and lose their killing power.
Chronic exposure to tumor antigens and inhibitory signals leads to T cell exhaustion, characterized by reduced effector cytokine production and cytotoxicity. Tumor-associated NK cells can regulate distinct CD8+ T cell differentiation programs that contribute to resistance against immune checkpoint blockers. Furthermore, CD8+ T cells can regulate tumor ferroptosis during cancer immunotherapy, indicating a complex interplay between T cell activity and tumor cell death pathways. These intrinsic changes reinforce the negative regulation of T cell mediated immune response to tumor cell.
Post-Transcriptional and Epigenetic Control
In simple terms: Chemical modifications on RNA and proteins can fine-tune the suppression of T cells.
The m6A modification of circIGF2BP3 promotes deubiquitination of PD-L1 in non-small cell lung cancer, leading to increased PD-L1 stability and enhanced inhibition of CD8+ T cell responses. This exemplifies how post-transcriptional mechanisms can sustain negative regulation of T cell mediated immune response to tumor cell. Such layers of control provide additional targets for therapeutic intervention.
Outcome: Tumor Immune Evasion
In simple terms: The end result is that the tumor escapes immune destruction and continues to grow.
The cumulative effect of these negative regulatory mechanisms is the suppression of T cell mediated killing, allowing tumors to evade immune surveillance and progress. This outcome is clinically manifested as resistance to immunotherapy and poor patient prognosis. Understanding the stages of this process is essential for designing strategies to reverse it.
Key Genes Involved in GO:0002841 negative regulation of T cell mediated immune response to tumor cell
The following genes and proteins are key players in the negative regulation of T cell mediated immune response to tumor cell, as supported by published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| CTLA-4 | Competes with CD28 for co-stimulatory ligands, delivering inhibitory signals to T cells | Target of ipilimumab; blockade enhances antitumor immunity |
| PD-L1 (CD274) | Binds PD-1 on T cells, delivering inhibitory signals | Target of anti-PD-L1 antibodies; its deubiquitination by circIGF2BP3 promotes immune evasion |
| PD-1 (PDCD1) | Inhibitory receptor on T cells; engagement by PD-L1 suppresses T cell function | Target of pembrolizumab/nivolumab; blockade induces responses by inhibiting adaptive immune resistance |
| AEBP1 | Secreted by cancer-associated fibroblasts to drive T cell dysfunction | Potential target to overcome fibroblast-mediated immunosuppression |
| circIGF2BP3 | m6A-modified circular RNA that promotes PD-L1 deubiquitination | Biomarker and therapeutic target in NSCLC |
| NK cells (tumor-associated) | Regulate CD8+ T cell differentiation programs and contribute to resistance against immune checkpoint blockers | Target for combination therapies to overcome resistance |
| Microbiota-modulated T cells | Immunosuppressive intestinal T cells that migrate into tumors | Potential target for microbiome-based interventions |
| Bile acids (microbiota-modified) | Suppress CD8+ T cell effector functions | Metabolic targets to enhance anti-tumor immunity |
| CD8+ T cells | Effector cells that kill tumor cells; their function is negatively regulated | Central to immunotherapy response; ferroptosis regulation |
| Ferroptosis regulators | CD8+ T cells regulate tumor ferroptosis during immunotherapy | Link between T cell activity and tumor cell death |
| Tregs | Suppress anti-tumor T cell responses | Target for depletion or inhibition |
| CAFs | Create immunosuppressive microenvironment | Target for stromal reprogramming |
| PD-L1 deubiquitinases | Stabilize PD-L1, enhancing inhibition | Potential drug targets |
| IFN-γ | Cytokine that can upregulate PD-L1 but also mediate anti-tumor effects | Biomarker of response |
| Tumor antigens | Provide targets for T cell recognition; their loss can lead to immune evasion | Vaccine and TCR-T targets |
| MHC class I | Presents tumor antigens to CD8+ T cells; downregulation leads to immune evasion | Predictive biomarker |
| Immune checkpoint ligands | Engage inhibitory receptors to suppress T cells | Therapeutic targets |
How Is negative regulation of T cell mediated immune response to tumor cell Regulated?
The process of negative regulation of T cell mediated immune response to tumor cell is itself tightly regulated at multiple levels. Transcriptional regulation of immune checkpoint molecules such as PD-L1 and CTLA-4 can be induced by inflammatory signals like IFN-γ. Post-transcriptional mechanisms, including m6A modification of circIGF2BP3, control PD-L1 protein stability. Epigenetic modifications and non-coding RNAs also contribute to the regulation of this process. Additionally, the composition of the gut microbiota can modulate systemic immune tone and the presence of immunosuppressive T cells in tumors. Metabolic factors such as bile acids act as signaling molecules that suppress CD8+ T cell function. Together, these regulatory layers ensure that T cell responses are kept in check, but in cancer they are hijacked to promote immune evasion.
negative regulation of T cell mediated immune response to tumor cell and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| PD-L1 (CD274) | Non-small cell lung cancer, immune evasion | KO and knock-in in NSCLC cell lines; syngeneic mouse models |
| CTLA-4 | Melanoma, antitumor immunity | KO mice; CTLA-4 blockade in tumor models |
| AEBP1 | Fibroblast-mediated T cell dysfunction in tumors | CAF-specific KO; co-culture with T cells |
| circIGF2BP3 | NSCLC immune evasion | Overexpression and knockdown in lung cancer cells; mouse xenografts |
| Bile acid receptors | Colorectal cancer growth and CD8+ T cell suppression | Germ-free mice; bile acid supplementation |
Cancer Immunotherapy Resistance
Negative regulation of T cell mediated immune response to tumor cell is a major cause of resistance to immune checkpoint inhibitors. Tumors that upregulate PD-L1 or recruit immunosuppressive cells can evade T cell attack despite checkpoint blockade. For example, tumor-associated NK cells contribute to resistance against immune checkpoint blockers by shaping CD8+ T cell differentiation. Understanding these mechanisms is crucial for developing combination therapies.
Colorectal Cancer and Microbiota
In colorectal cancer, microbiota-modified bile acids promote tumor growth by suppressing CD8+ T cell effector functions. This highlights how the gut microbiome can systemically influence the negative regulation of anti-tumor immunity. Additionally, microbiota-modulated checkpoint directs immunosuppressive intestinal T cells into cancers, further linking microbial signals to immune evasion.
Non-Small Cell Lung Cancer
In non-small cell lung cancer, the m6A-modified circIGF2BP3 inhibits CD8+ T cell responses by promoting deubiquitination of PD-L1, leading to immune evasion. This exemplifies a post-transcriptional mechanism that sustains negative regulation of T cell mediated immune response to tumor cell. Targeting this pathway could improve immunotherapy outcomes.
Fibroblast-Mediated Immunosuppression
Cancer-associated fibroblasts can drive T cell dysfunction through secreted factors like AEBP1, contributing to negative regulation of T cell mediated immune response to tumor cell. This stromal component is a promising target for overcoming immunotherapy resistance.
From negative regulation of T cell mediated immune response to tumor cell-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does knockout of CTLA-4 enhance anti-tumor T cell responses? | CTLA-4 KO mice or CRISPR KO in T cells |
| Does point mutation in PD-L1 affect its binding to PD-1? | PD-L1 point-mutant knock-in cell lines |
| Can knock-in of a tagged PD-L1 reveal its trafficking? | Tagged PD-L1 knock-in in tumor cells |
| Does overexpression of circIGF2BP3 promote immune evasion? | CircIGF2BP3 overexpression in NSCLC cells |
| What is the role of AEBP1 in CAF-mediated T cell suppression? | AEBP1 KO in cancer-associated fibroblasts |
| How do microbiota-modified bile acids affect CD8+ T cells? | Bile acid receptor KO mice; fecal transplant |
How to Study the negative regulation of T cell mediated immune response to tumor cell Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout screen | Loss-of-function effects on T cell mediated killing | Identify negative regulators of anti-tumor immunity |
| Co-culture cytotoxicity assay | T cell killing of tumor cells | Test checkpoint blockade or gene KO |
| RNA-seq | Transcriptional changes | Discover pathways of immune evasion |
| Proteomics | Protein expression and modifications | Identify post-translational regulation |
| Flow cytometry | T cell activation and exhaustion markers | Assess T cell function in tumors |
| Multiplex imaging | Spatial distribution of immune cells | Study tumor microenvironment |
| In vivo tumor growth | Tumor progression and response to therapy | Evaluate therapeutic targets |
| Microbiome analysis | Microbial composition and metabolites | Link microbiota to immune regulation |
Functional Immune Assays
To study negative regulation of T cell mediated immune response to tumor cell, researchers use co-culture assays of T cells with tumor cells and measure T cell activation, proliferation, and cytotoxicity. For example, CTLA-4 blockade enhances antitumor immunity in such assays. PD-1 blockade responses can be assessed by measuring T cell effector functions.
CRISPR Screens
Genome-wide CRISPR knockout screens can identify genes whose loss enhances T cell mediated killing of tumor cells, thereby uncovering negative regulators. Such screens have been instrumental in discovering checkpoint molecules and their regulators.
Transcriptomics and Proteomics
RNA-seq and proteomics can reveal changes in gene expression and protein stability associated with negative regulation. For instance, m6A-modified circIGF2BP3 was found to promote PD-L1 deubiquitination through such approaches. Single-cell RNA-seq can dissect T cell states in the tumor microenvironment.
In Vivo Tumor Models
Syngeneic mouse tumor models are used to test the impact of gene knockouts or treatments on tumor growth and T cell infiltration. CTLA-4 blockade was shown to enhance antitumor immunity in vivo. Tumor-associated NK cell depletion can reverse resistance to checkpoint blockers.
How CRISPR Can Be Used to Study GO:0002841 negative regulation of T cell mediated immune response to tumor cell
Knockout
CRISPR knockout of candidate genes such as CTLA-4 or PD-L1 can reverse negative regulation and enhance T cell mediated tumor killing. Knockout models are essential for validating targets identified in screens.
Point Mutation
Point mutations can be introduced to dissect specific domains or residues required for inhibitory function, such as PD-L1 residues critical for PD-1 binding. This helps understand structure-function relationships.
Knock-in
Knock-in of tagged versions of proteins (e.g., GFP-PD-L1) allows tracking of localization and interactions in live cells. Knock-in of reporter genes can also monitor pathway activity.
Overexpression
Overexpression of negative regulators like circIGF2BP3 can drive immune evasion and resistance to immunotherapy, providing models to test countermeasures. Overexpression in tumor cells followed by co-culture with T cells reveals suppressive mechanisms.
How EDITGENE Supports negative regulation of T cell mediated immune response to tumor cell Research
Researchers studying negative regulation of T cell mediated immune response to tumor cell-related genes often need to determine whether a candidate gene is causally involved in suppressing anti-tumor immunity. This requires precise genetic manipulation and functional validation in relevant models.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of T cell mediated immune response to tumor cell research.
Frequently Asked Questions About negative regulation of T cell mediated immune response to tumor cell
What is GO:0002841?
GO:0002841 is the Gene Ontology term for negative regulation of T cell mediated immune response to tumor cell, defined as any process that stops, prevents, or reduces the frequency, rate, or extent of a T cell mediated immune response to tumor cell.
What genes are involved in negative regulation of T cell mediated immune response to tumor cell?
Key genes include CTLA-4, PD-L1 (CD274), PD-1 (PDCD1), AEBP1, and circIGF2BP3, among others.
How does CTLA-4 negatively regulate T cell mediated immune response to tumor cell?
CTLA-4 competes with CD28 for co-stimulatory ligands, delivering inhibitory signals that dampen T cell activation; its blockade enhances antitumor immunity.
What is the role of PD-L1 in this process?
PD-L1 binds PD-1 on T cells, delivering inhibitory signals; its deubiquitination by circIGF2BP3 promotes immune evasion in NSCLC.
How do cancer-associated fibroblasts contribute to negative regulation?
CAFs secrete factors like AEBP1 that drive T cell dysfunction, creating an immunosuppressive microenvironment.
Can microbiota influence negative regulation of T cell mediated immune response to tumor cell?
Yes, microbiota-modified bile acids suppress CD8+ T cell effector functions, and microbiota-modulated T cells can migrate into tumors.
What experimental models are used to study GO:0002841?
Common models include CRISPR knockout mice or cell lines, syngeneic tumor models, co-culture assays, and CRISPR screens.
How does tumor-associated NK cell activity relate to this term?
Tumor-associated NK cells regulate CD8+ T cell differentiation programs and contribute to resistance against immune checkpoint blockers.
What is the link between ferroptosis and negative regulation of T cell mediated immune response to tumor cell?
CD8+ T cells can regulate tumor ferroptosis during cancer immunotherapy, indicating a complex interplay.
Why is GO:0002841 important for cancer immunotherapy?
It represents the primary mechanism of immune evasion and resistance to checkpoint inhibitors, making it a key target for new therapies.
Conclusion
GO:0002841, negative regulation of T cell mediated immune response to tumor cell, is a central biological process in cancer immunology that encompasses diverse mechanisms of immune evasion. From checkpoint molecules like CTLA-4 and PD-L1 to microenvironmental factors such as AEBP1 and microbiota-derived bile acids, multiple layers of regulation suppress T cell mediated tumor killing. Understanding these pathways is essential for developing effective immunotherapies and overcoming resistance. Continued research using CRISPR models and functional genomics will uncover new targets to reverse this negative regulation and improve patient outcomes.
References
- 1. Leach DR et al.. 1996. Enhancement of antitumor immunity by CTLA-4 blockade.. Science 271(5256):1734-6 PMID: 8596936
- 2. Wang W et al.. 2019. CD8(+) T cells regulate tumour ferroptosis during cancer immunotherapy.. Nature 569(7755):270-274 PMID: 31043744
- 3. Wang X et al.. 2025. AEBP1 drives fibroblast-mediated T cell dysfunction in tumors.. Nat Commun 16(1):8171 PMID: 40890191
- 4. Cong J et al.. 2024. Bile acids modified by the intestinal microbiota promote colorectal cancer growth by suppressing CD8(+) T cell effector functions.. Immunity 57(4):876-889.e11 PMID: 38479384
- 5. Tumeh PC et al.. 2014. PD-1 blockade induces responses by inhibiting adaptive immune resistance.. Nature 515(7528):568-71 PMID: 25428505
- 6. Song NJ et al.. 2025. Tumor-associated NK Cells Regulate Distinct CD8+ T-cell Differentiation Program in Cancer and Contribute to Resistance against Immune Checkpoint Blockers.. Cancer Discov 15(9):1835-1857 PMID: 40530506
- 7. Fidelle M et al.. 2023. A microbiota-modulated checkpoint directs immunosuppressive intestinal T cells into cancers.. Science 380(6649):eabo2296 PMID: 37289890
- 8. Liu Z et al.. 2021. N(6)-methyladenosine-modified circIGF2BP3 inhibits CD8(+) T-cell responses to facilitate tumor immune evasion by promoting the deubiquitination of PD-L1 in non-small cell lung cancer.. Mol Cancer 20(1):105 PMID: 34416901
